Procalcitonin in Hepatocellular Carcinoma

the value of serum procalcitonin in differentiation between bacterial infection and non infectious inflammation in febrile HCC patients following locoeregional treatment for HCC.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatocellular Carcinoma Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Tropical medicine department and hepatocellular carcinoma clinic

Cairo, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

- Hepatocellular carcinoma patients who will undergo TACE and/or radio-frequency.
- Fever more than 38C after 48 hours post intervention.

Exclusion criteria

HCC Patients who does not develop fever after intervention.
Proven infection elsewhere (e.g. UTI, chest infection..)

Treatment and study plan

Primary outcomes

Differantiate between post- embolization syndrom and sepsis following locoregional treatment for hepatocellular carcinoma

Time frame: 6months

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Role of Procalcitonin in Differantiation Between Bacerial Infection and Non Infectious Inflammation in Febrile Hepatocellular Carcinoma Patients After Locoregional Treatment

Important dates

Study start: 2012
Primary completion: 2012
Study completion: 2013
First posted: Jan 26, 2012
Registry last updated: Oct 1, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed